Nivolumab

Nadeem Riaz1, Jonathan J Havel2, Vladimir Makarov3

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cell
|October 17, 2017
PubMed
概括

通过减少突变和对黑色素瘤新抗原进行选择,尼沃卢马布的免疫检查点阻塞改变了瘤的演变. 这种疗法还重塑瘤免疫微环境, 增强T细胞的反应.